| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/03/2003 | WO2003053997A2 Methods of increasing endogenous erythropoietin (epo) |
| 07/03/2003 | WO2003053977A1 Tetracyclic heterocompounds as estrogen receptor modulators |
| 07/03/2003 | WO2003053971A1 Pyridoquinoxaline antivirals |
| 07/03/2003 | WO2003053966A2 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 07/03/2003 | WO2003053923A2 Pyrrolidine derivatives as prostaglandin modulators |
| 07/03/2003 | WO2003053922A2 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| 07/03/2003 | WO2003053921A2 Mutant proteinase inhibitors and uses thereof |
| 07/03/2003 | WO2003053522A1 Methods of treating bacterial infections in dogs and cats |
| 07/03/2003 | WO2003053474A2 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 07/03/2003 | WO2003053468A1 Method for obtaining the elimination of integrated and functional viruses from infected mammal cells |
| 07/03/2003 | WO2003053467A1 Drug for regenerating tissue and vessel and method therefor |
| 07/03/2003 | WO2003053446A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 07/03/2003 | WO2003053442A1 Tempamine compositions and methods of use |
| 07/03/2003 | WO2003053441A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
| 07/03/2003 | WO2003053440A1 Medicinal composition |
| 07/03/2003 | WO2003053436A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 07/03/2003 | WO2003053435A1 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 07/03/2003 | WO2003053431A2 Pharmaceutical compositions based on azetidine derivatives |
| 07/03/2003 | WO2003053407A1 Liposomal delivery of vitamin e based compounds |
| 07/03/2003 | WO2003053400A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | WO2003053364A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 07/03/2003 | WO2003053360A2 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/03/2003 | WO2003053358A2 Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function |
| 07/03/2003 | WO2003053354A2 Fused cyclic modulators of nuclear hormone receptor function |
| 07/03/2003 | WO2003053353A2 Administration of vasopeptidase inhibitors to reduce pulse pressure |
| 07/03/2003 | WO2003053347A2 Galliumcomplexes of 3-hydroxy-4-pyrones to treat mycobacterial infections |
| 07/03/2003 | WO2003053346A2 Systems and methods for treating patients with processed lipoaspirate cells |
| 07/03/2003 | WO2003053334A2 Compositions and methods for the diagnosis and treatment of tumor |
| 07/03/2003 | WO2003053292A1 Vaginal delivery of drugs |
| 07/03/2003 | WO2003053224A2 Novel compositions and methods for cancer |
| 07/03/2003 | WO2003053219A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/03/2003 | WO2003053215A2 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 07/03/2003 | WO2003053136A2 Triple transgenic mouse model of alzheimer's disease |
| 07/03/2003 | WO2003030823A3 Combinations for the treatment of immunoinflammatory disorders |
| 07/03/2003 | WO2003029488A3 A method for the early detection of cancer |
| 07/03/2003 | WO2003026643A3 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| 07/03/2003 | WO2003026611A3 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 07/03/2003 | WO2003016499A3 Combinatorial methods for inducing cancer cell death |
| 07/03/2003 | WO2002101009A3 Structural and cytoskeleton-associated proteins |
| 07/03/2003 | WO2002098898A3 FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 07/03/2003 | WO2002070657A3 93870, a human g-protein coupled receptor and uses therefor |
| 07/03/2003 | WO2002058734A3 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 07/03/2003 | WO2002058732A3 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 07/03/2003 | WO2002050279A3 Nucleic acid-associated proteins |
| 07/03/2003 | WO2002020849A3 Gene markers useful for detecting skin damage in response to ultraviolet radiation |
| 07/03/2003 | WO2002006317A3 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/03/2003 | WO2000074667A3 Compositions active in telomere damage comprising a taxane and telomerase inhibitor |
| 07/03/2003 | US20030125659 Dosage of transdermal delivery systems |
| 07/03/2003 | US20030125657 Comprises ligand for human immunoglobulin for immunoapheresis, which mimicks sequence of an adrenergic receptor structure |
| 07/03/2003 | US20030125537 Neovascularization; platelet derived growth factors; vascular permeability factors; wound healing agents; antitumor/antiproliferative agents; antisense agents; for treatment of intestinal malabsorption syndrome |
| 07/03/2003 | US20030125533 Regulation of human sphingosine kinase-like protein |
| 07/03/2003 | US20030125388 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 07/03/2003 | US20030125378 Skin treatment, cosmetics |
| 07/03/2003 | US20030125374 Enhancement of taxane-based chemotherapy by a CDK1 antagonist |
| 07/03/2003 | US20030125362 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 07/03/2003 | US20030125359 RAF-MEK-ERK pathway inhibitors to treat cancer |
| 07/03/2003 | US20030125351 Administering a heterocyclic amide compound to a glaucoma patient for inhibiting contraction of ciliary muscle; Rho kinase inhibitor |
| 07/03/2003 | US20030125347 An oral dosage form containing an opiate and a capsaicinoid irritant, opiate is selected from codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, oxycodone and their salts for the traeatment of drug abuse |
| 07/03/2003 | US20030125343 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 07/03/2003 | US20030125338 Compounds, compositions and methods for modulating beta-amyloid production |
| 07/03/2003 | US20030125335 Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| 07/03/2003 | US20030125334 5-HT receptor ligands and uses thereof |
| 07/03/2003 | US20030125326 Farnesyl protein transferase inhibitor combinations |
| 07/03/2003 | US20030125319 Administering an estrogen agonist/ antagonist while reducing the side effects associated with estrogen administration; urinary and vaginal infections; incontinence; vaginal dryness; kits for assessing vaginal health |
| 07/03/2003 | US20030125317 Vitronectin receptor antagonists |
| 07/03/2003 | US20030125316 Cardiovascular disorders including atherosclerosis and other coronary artery disease; anticholesterol agents; antilipemia agents; nontoxic; prophylactic; e.g., 2,3,4,5-tetrahydro-1-benzothiepine 1,1-dioxide and nicotinic acid or nigeritrol |
| 07/03/2003 | US20030125312 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation- related cardiovascular disorders |
| 07/03/2003 | US20030125305 Treating patients who have become resistant to a Brc-Abl tyrosine kinase inhibitor, e.g., imatinib mesylate, with a nucleoside analog of a 2-cytosinyl-1,3-dioxolane; chronic myelogenous leukemia in blastic phase; anticarcinogenic agents |
| 07/03/2003 | US20030125301 Blocking postprandial glycemic response by feeding a dual induced viscosity fiber system of soluble fiber, water-insoluble, acid- soluble metal or metal compound (calcium carbonate) and a hydrolyzed starch; dietetics; |
| 07/03/2003 | US20030125299 Method for treating or preventing inflammatory diseases |
| 07/03/2003 | US20030125298 Administering a compound selected from the group of adenosine deaminase inhibitors and adenosine monophosphate deaminase inhibitors to a tumor with elevated adenosine in the tumor cells or extracellular fluid; cancers of cells/organs |
| 07/03/2003 | US20030125290 Cancer treatment with a synthetic sequences |
| 07/03/2003 | US20030125282 Treating fertility disorders; maternal-antigen-that-embryos-require (MATER) |
| 07/03/2003 | US20030125281 Compositions and processes using siRNA, amphipathic compounds and polycations |
| 07/03/2003 | US20030125268 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 07/03/2003 | US20030125265 Administering to a cancer paient a compound (emodin, genistein) having anti-estrogen receptor activity and tyrosine kinase inhibitor activity to prevent esterogen receptor positive cancer cells |
| 07/03/2003 | US20030125262 Methods and reagents for regulation of cellular responses in biological systems |
| 07/03/2003 | US20030125257 A olilgopeptide or polypeptide containing Leustatin, Chastatin or Tyrstatin |
| 07/03/2003 | US20030125252 Administering to a vertebrate an effective osteogenesis stimulating amount of an RAR (retinoic acid receptor) antagonist to treat both metabolic or non-metabolic diseases; RAR antisense oligonucleotide |
| 07/03/2003 | US20030125235 Treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated with cytokine production, for treatment |
| 07/03/2003 | US20030124690 Novel compounds |
| 07/03/2003 | US20030124678 Interleukin-2 mutants with reduced toxicity |
| 07/03/2003 | US20030124655 Receptor protein specifically recognizing bacterial dna |
| 07/03/2003 | US20030124649 Membrane associated proteins |
| 07/03/2003 | US20030124602 Tumour suppresor and uses thereof |
| 07/03/2003 | US20030124598 PGC-1beta, a novel PGC-1 homologue and uses therefor |
| 07/03/2003 | US20030124596 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 07/03/2003 | US20030124593 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 07/03/2003 | US20030124582 Polypeptide encoded by a polynucleotide of given sequence; detecting the effect of a test compound on the production of mRNA; use in identifying agonists/antagonists that may be useful in therapy |
| 07/03/2003 | US20030124575 Dendritic cells; antigen presenting cells; g-protein coupled receptors; immunotherapy; antiinflammatory agents; antitumor agents; viricides; drug screening |
| 07/03/2003 | US20030124550 Method of screening drug for hepatitis C |
| 07/03/2003 | US20030124540 Interventions to mimic the effects of calorie restriction |
| 07/03/2003 | US20030124534 Measuring expression of nucleotide sequences in cells |
| 07/03/2003 | US20030124529 Pregnancy-associated plasma protein-A2 (PAPP-A2) |
| 07/03/2003 | US20030124513 RNA interfering molecule which modulates gene expression; human immunodeficiency virus (HIV); configurations; cleavage |
| 07/03/2003 | US20030124200 Sucralose, glucosamine and a beverage base, especially fruit juice; cartilage supplements include chondroitin, glucosamine, and hyaluronic acid |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124190 Methods and compositions for treating pain of the mucous membrane |
| 07/03/2003 | US20030124184 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant |
| 07/03/2003 | US20030124161 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |